TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab: review decision - September 2012
Review of NICE Technology Appraisal Guidance No. 172; Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck
The Institute was proposing the TA172 should be transferred to the 'static list' as there is no new evidence that might lead to a change in the recommendations.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute's Guidance Executive has decided to proceed with the proposal.
TA172 will therefore be transferred to the static list, which can be found here.
This page was last updated: 28 September 2012